[HTML][HTML] Drug discovery for cutaneous leishmaniasis: a review of developments in the past 15 years

HN Corman, CW McNamara, MA Bakowski - Microorganisms, 2023 - mdpi.com
Leishmaniasis is a group of vector-borne, parasitic diseases caused by over 20 species of
the protozoan Leishmania spp. The three major disease classifications, cutaneous, visceral …

Naphthoquinones and derivatives for chemotherapy: perspectives and limitations of their anti-trypanosomatids activities

L Dantas-Pereira, EF Cunha-Junior… - Current …, 2021 - ingentaconnect.com
Chagas disease, Sleeping sickness and Leishmaniasis, caused by trypanosomatids
Trypanosoma cruzi, Trypanosoma brucei and Leishmania spp., respectively, are considered …

Effects of anti‐Leishmania compounds in the behavior of the sand fly vector Lutzomyia longipalpis

TN Ferreira, RP Brazil, MA McDowell… - Pest Management …, 2022 - Wiley Online Library
BACKGROUND Leishmaniasis is an infectious parasitic disease caused by pathogens of
the genus Leishmania transmitted through the bite of adult female sand flies. To reduce case …

[HTML][HTML] Colombian contributions fighting Leishmaniasis: A systematic review on antileishmanials combined with chemoinformatics analysis

J Sánchez-Suárez, FA Bernal, E Coy-Barrera - Molecules, 2020 - mdpi.com
Leishmaniasis is a parasitic morbid/fatal disease caused by Leishmania protozoa. Twelve
million people worldwide are appraised to be currently infected, including ca. two million …

[HTML][HTML] Efficacy of spironolactone treatment in murine models of cutaneous and visceral leishmaniasis

VV Andrade-Neto, J da Silva Pacheco… - Frontiers in …, 2021 - frontiersin.org
Translational studies involving the reuse and association of drugs are approaches that can
result in higher success rates in the discovery and development of drugs for serious public …

[HTML][HTML] In silico antiprotozoal evaluation of 1, 4-naphthoquinone derivatives against chagas and leishmaniasis diseases using QSAR, molecular docking, and ADME …

LS Prieto Cárdenas, KA Arias Soler… - Pharmaceuticals, 2022 - mdpi.com
Chagas and leishmaniasis are two neglected diseases considered as public health
problems worldwide, for which there is no effective, low-cost, and low-toxicity treatment for …

[HTML][HTML] The pterocarpanquinone LQB 118 inhibits inflammation triggered by zymosan in vivo and in vitro

É de Almeida Lima, LHA Cavalcante-Silva… - International …, 2020 - Elsevier
LQB 118, a hydride molecule, has been described as an antineoplastic and antiparasitic
drug. Recently, LQB118 was also shown to display anti-inflammatory properties using an …

Estudo de parâmetros fisiológicos de Lutzomyia longipalpis: avaliação do efeito de compostos anti-Leishmania e determinação de idade

TN Ferreira - 2022 - arca.fiocruz.br
As leishmanioses são doenças causadas por parasitos do gênero Leishmania, que são
transmitidos pela picada de flebotomíneos. Para controle da transmissão e redução do …

Potencial terapêutico da pterocarpanoquinona LQB-118 na infecção pelo Trypanosoma cruzi

ACS Brito - 2020 - bdtd.uerj.br
RESUMO BRITO, Andréia Carolinne de Souza. Potencial terapêutico da
pterocarpanoquinona LQB-118 na infecção pelo Typanosoma cruzi. 2020. 119 f. Tese …

A review on the novel Heterocyclic Antileishmanial drugs for the treatment of Leishmaniasis

A Ibnat - 2019 - dspace.bracu.ac.bd
New antileishmanialdrugs must be developed to make the treatment of leishmaniasis
available for the people all over the world. It must be ensured that every single person has …